查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1978779

特发性肺纤维化市场：按治疗分类、给药途径、通路和最终用户划分 - 全球预测 2026-2032 年

Idiopathic Pulmonary Fibrosis Market by Therapeutic Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，特发性肺纤维化市场价值将达到 41.9 亿美元，到 2026 年将成长至 44.2 亿美元，到 2032 年将达到 61.9 亿美元，年复合成长率为 5.71%。

主要市场统计数据
基准年 2025 41.9亿美元
预计年份：2026年 44.2亿美元
预测年份 2032 61.9亿美元
复合年增长率 (%) 5.71%

特发性肺纤维化的临床和操作介绍：重点关注诊断的复杂性、治疗进展和不断发展的护理路径。

特发性肺纤维化 (IPF) 是一种持续且复杂的临床挑战，需要在诊断、治疗和护理的各个方面协调推进。其症状通常特异性，且与其他慢性呼吸系统疾病的症状重迭，给临床医生早期发现疾病带来了障碍。同时，确诊需要高解析度影像学检查、肺功能检查以及多学科会诊。这些诊断方面的现实情况会延迟疾病修正治疗的启动，并使病程管理更加复杂，凸显了建立更清晰的临床路径和改善诊断资源获取途径的迫切需求。

变革性的科学、监管和交付模式的改变正在重塑特发性肺纤维化患者的治疗和护理的发展。

由于科学、监管和给药模式的动态动态，特发性肺纤维化 (IPF) 的治疗和护理格局正在经历变革性变化。分子生物学和转化研究的进步加深了我们对纤维化路径的理解，为探索补充或增强现有抗纤维化策略的新作用机制开闢了可能性。同时，监管机构也越来越接受适应性方法和基于真实世界证据的方法，这些方法能够以令人信服的机制证据缩短药物研发週期。这也正在改变申办者对候选药物的优先排序和临床实验方案的设计方式。

对 2025 年美国关税调整对供应链、价格波动以及 IPF 患者获得治疗的累积影响进行全面分析。

2025年的贸易政策趋势和关税调整为IPF供应链、药品原料采购以及治疗药物和医疗设备的跨境分销带来了复杂的局面。累积的关税措施可能会增加从世界各地采购的药品活性成分和辅料的投入成本，迫使製造商重新评估其供应商组合和原材料筹资策略。因此，企业可能会采取双重采购、近岸外包或垂直整合等策略，以确保供应的连续性并降低地缘政治波动带来的风险。

从治疗领域、给药途径、分销管道和医疗保健环境等方面的差异出发，制定详细的细分观点，从而推动商业和临床策略的发展。

细分市场层面的差异化是特发性肺纤维化（IPF）相关人员进行策略决策的基础，需要对治疗领域、给药途径、分销网络和终端用户环境有深入的了解。基于治疗领域，我们分析了抗纤维化药物和免疫抑制剂。抗纤维化药物进一步细分为尼达尼布和Pirfenidone，免疫抑制剂进一步细分为糖皮质激素和免疫调节剂。糖皮质激素包括Methylprednisolone和泼尼松，而免疫调节剂包括Azathioprine和Mycophenolate Mofetil。每种药物都有不同的临床特征和耐受性，这些都会影响处方行为。

深入分析美洲、欧洲、中东、非洲和亚太地区不同的医疗保健系统、报销框架和就医途径。

区域趋势显着影响特发性肺纤维化（IPF）治疗的临床实践模式、监管预期和商业性路径，因此需要製定能够反映各地区医疗体系结构和报销环境的策略。在美洲，优秀医疗中心的集中以及保险公司与医疗服务提供者之间成熟的合作模式，使得指南推荐疗法的推广应用相对迅速。然而，都市区之间以及公立和私立保险公司在医疗服务取得方面仍然存在差异。同时，临床网路和远端医疗的普及正在改变患者从诊断到接受专科治疗的流程。

主要企业层面洞察，整合了成熟企业在 IPF 治疗方面的优势、新兴创新的发展轨迹以及管道和服务合作伙伴关係日益增长的重要性。

特发性肺纤维化（IPF）领域的竞争格局包括成熟的製药公司、新兴生物技术公司和专业经销商，它们各自在临床开发、商业化和患者支持方面拥有独特的优势。成熟的製药公司在生产方面具有规模经济效益，拥有丰富的全球监管经验和广泛的支付方网络，这使其能够加快产品上市和医保报销谈判。同时，新兴生物技术公司通常开发差异化的作用机制和标靶联合治疗，以解决尚未明确的生物学通路，从而创造策略合作和授权的机会。

产业领导者在协调证据产生、供应链韧性、数位化医疗整合和区域市场进入规划方面面临的可操作策略挑战

为了显着改善特发性肺纤维化 (IPF) 患者的治疗效果，产业领导者必须采取果断行动，将临床创新与永续的医疗服务取得和交付模式相结合。首先，应投资于产生可靠的实证医学证据，将随机对照试验数据与真实世界的疗效和安全性终点相结合，以支持与支付者的对话并更新临床指南。在推动实证策略的同时，应建立灵活的供应链，制定短期紧急时应对计画并实现供应商的策略多元化，以确保患者能够稳定地获得治疗，同时降低关税和地缘政治风险。

高度透明的多来源调查方法，结合了专家的直接访谈、临床文献的整合以及基于情境的供应链风险分析。

本报告的调查方法整合了多来源证据、对专科临床医生的访谈以及严谨的定性分析，以确保提供可靠的实践见解。主要调查包括对呼吸科专家、临床试验专家、供应链经理和医保报销专家进行结构化访谈，以了解他们对诊断路径、治疗决定因素和营运瓶颈的实际观点。次要调查则利用同侪审查文献、监管指导文件、临床指南和产品专论来检验临床声明和治疗背景。

简明结论强调了整合证据、营运韧性和相关人员合作的必要性：这些将把特发性肺纤维化 (IPF) 的创新与改善患者预后联繫起来。

总之，特发性肺纤维化的治疗格局正进入一个实践创新阶段，在治疗方法的进步、医疗服务模式的演变以及贸易格局变化的推动下，治疗的可及性和治疗效果正在改变。对疾病机制和新型治疗策略的深入理解为改变疾病进程提供了真正的契机，但要实现这一潜力，需要协调一致地投资于循证医学、保障医疗资源供应以及以患者为中心的护理模式。积极将临床开发与支付方需求和实际运作结合的相关人员，最能将科学进步转化为病患的永续价值。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗分类分類的特发性肺纤维化市场

  • 抗纤维化药物
    • 任天堂
    • Pirfenidone
  • 免疫抑制剂
    • 皮质类固醇
      • Methylprednisolone
      • 强的松
    • 免疫调节剂
      • Azathioprine
      • Mycophenolate Mofetil

第九章：特发性肺纤维化市场：依给药途径划分

  • 吸入
  • 注射药物
  • 口服

第十章：特发性肺纤维化市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
  • 专科药房

第十一章：特发性肺纤维化市场：以最终用户划分

  • 门诊部
  • 家庭医疗保健设施
  • 医院
  • 专科诊所

第十二章：特发性肺纤维化市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：特发性肺纤维化市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：特发性肺纤维化市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国特发性肺纤维化市场

第十六章：中国特发性肺纤维化市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • GNI Group Ltd.
  • Horizon Therapeutics PLC by Amgen Inc.
  • Johnson & Johnson
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
Product Code: MRR-2A0283E25610

The Idiopathic Pulmonary Fibrosis Market was valued at USD 4.19 billion in 2025 and is projected to grow to USD 4.42 billion in 2026, with a CAGR of 5.71%, reaching USD 6.19 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.19 billion
Estimated Year [2026] USD 4.42 billion
Forecast Year [2032] USD 6.19 billion
CAGR (%) 5.71%

A clinical and operational introduction to idiopathic pulmonary fibrosis highlighting diagnostic complexity, therapeutic progress, and evolving care pathways

Idiopathic pulmonary fibrosis (IPF) presents a persistent and complex clinical challenge that demands coordinated advances across diagnosis, therapeutics, and care delivery. Clinicians face hurdles in early identification because symptoms are often nonspecific and overlap with other chronic respiratory conditions, while diagnostic confirmation relies on high-resolution imaging, pulmonary function testing, and multidisciplinary consensus. These diagnostic realities delay initiation of disease-modifying therapies and complicate longitudinal management, increasing the imperative for clearer clinical pathways and improved access to diagnostic resources.

Concurrently, therapeutic evolution has introduced disease-modifying antifibrotics alongside legacy immunomodulatory approaches, reshaping clinical paradigms for slowing fibrosis progression and preserving lung function. Health systems now balance the clinical benefits of newer agents with considerations of tolerability, drug interactions, and long-term adherence. As stakeholders refine treatment algorithms, the field is witnessing greater emphasis on biomarkers, personalized risk stratification, and integrated care models that bridge hospital-based specialty clinics with ambulatory and home-based services. This shifting clinical landscape underscores the need for strategic alignment between clinical practice, product development, and payer engagement to optimize patient outcomes.

Transformative scientific, regulatory, and delivery-model shifts that are reshaping therapeutic development and care for idiopathic pulmonary fibrosis patients

The landscape for IPF care and therapy is undergoing transformative shifts driven by scientific, regulatory, and delivery-model forces. Advances in molecular biology and translational research have sharpened understanding of fibrogenic pathways, creating opportunities for novel mechanisms to complement or enhance existing antifibrotic strategies. At the same time, regulatory agencies are increasingly receptive to adaptive and real-world evidence approaches that shorten development timelines for agents with compelling mechanistic rationale, which in turn changes how sponsors prioritize assets and design pivotal programs.

On the delivery side, digital health tools and remote monitoring are moving from pilot projects into substantive components of chronic respiratory disease management. These technologies support earlier intervention, enable closer adherence monitoring, and facilitate value-based contracting discussions with payers. Additionally, shifts in reimbursement paradigms toward outcomes-based arrangements are incentivizing payers and providers to collaborate on adherence, adverse event mitigation, and optimized sequencing of therapies. Taken together, these forces are creating a more dynamic ecosystem where clinical innovation, regulatory flexibility, and commercial strategy must be tightly coordinated to realize therapeutic and health-economic value.

Comprehensive analysis of the projected cumulative effects of 2025 United States tariff adjustments on supply chains, pricing dynamics, and patient access in IPF care

Trade policy developments and tariff adjustments in 2025 present a complex backdrop for IPF supply chains, drug ingredient sourcing, and cross-border distribution of therapeutics and devices. Cumulative tariff measures can increase input costs for active pharmaceutical ingredients and excipients that are sourced globally, requiring manufacturers to reassess supplier portfolios and raw material procurement strategies. As a result, companies may pursue dual-sourcing, nearshoring, or vertical integration to preserve supply continuity and mitigate exposure to geopolitical volatility.

Beyond procurement, tariff-induced cost pressures can cascade into pricing negotiations and reimbursement dialogues. Payers and integrated delivery networks are likely to scrutinize cost drivers more closely, prompting manufacturers to provide robust value and outcomes data to support formulary positioning. In parallel, distribution partners and specialty pharmacies may adapt contracting structures to absorb or pass through cost increases, influencing patient access pathways and adherence programs. Therefore, firms operating in the IPF space should evaluate tariff scenarios within their commercial risk frameworks, stress test supply chain resilience, and proactively engage stakeholders to preserve uninterrupted patient access to essential therapies.

In-depth segmentation perspective synthesizing therapeutic class, administration route, distribution channel, and care setting distinctions that drive commercial and clinical strategy

Segment-level differentiation underpins strategic decision-making for IPF stakeholders, requiring nuanced understanding of therapeutic classes, administration routes, distribution networks, and end-user settings. Based on therapeutic class, the landscape is studied across Antifibrotics and Immunosuppressants, with Antifibrotics further distinguished by Nintedanib and Pirfenidone and Immunosuppressants further subdivided into Corticosteroids and Immunomodulators; the Corticosteroids segment includes Methylprednisolone and Prednisone while Immunomodulators include Azathioprine and Mycophenolate Mofetil, each presenting distinct clinical profiles and tolerability considerations that influence prescribing behavior.

Route of administration considerations separate inhalation, injectable, and oral modalities, which in turn affect adherence patterns, monitoring requirements, and outpatient versus inpatient utilization. Distribution channel dynamics encompass Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Specialty Pharmacies, shaping how therapies are dispensed and what support services accompany treatment initiation and maintenance. End-user segmentation spans Ambulatory Care Centers, Home Healthcare Facilities, Hospitals, and Specialty Clinics, each with varied capacity for diagnostics, pulmonary rehabilitation, and complex therapy management. Integrating these segmentation lenses enables stakeholders to identify where clinical need, commercial opportunity, and operational friction intersect, and to prioritize interventions that reduce patient burden while improving therapeutic outcomes.

Detailed regional insights that reconcile differing healthcare systems, reimbursement frameworks, and access pathways across the Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics significantly influence clinical practice patterns, regulatory expectations, and commercial pathways for IPF therapies, requiring strategies that reflect local healthcare system structures and reimbursement environments. In the Americas, concentrated centers of excellence and integrated payer-provider models support relatively rapid uptake of guideline-endorsed therapies, yet access variability persists across urban and rural settings and between public and private payers. Meanwhile, clinical networks and telehealth diffusion are changing how patients navigate from diagnosis to specialty care.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous reimbursement systems create a mosaic of pricing and access conditions that necessitate differentiated market entry strategies and localized evidence generation. Stakeholders often prioritize health technology assessment alignment and real-world data collection to support country-specific value dossiers. Across Asia-Pacific, rapid healthcare modernization, growing specialty care capacity, and evolving domestic manufacturing capabilities are reshaping supply chains and commercial models, while variable affordability considerations and differing clinical guideline adoption timelines require tailored engagement with local clinicians and payers. Appreciating these regional nuances is essential for developing implementation plans that respect local standards of care and maximize patient access.

Key company-level insights synthesizing incumbent advantages, emergent innovation trajectories, and the rising importance of channel and service partnerships in IPF care

The competitive landscape for IPF encompasses established pharmaceutical sponsors, emerging biotechs, and specialty distributors, each contributing distinct capabilities across clinical development, commercialization, and patient support. Established companies bring scale in manufacturing, global regulatory experience, and broad payer relationships that can accelerate product rollout and reimbursement negotiations. Emerging biotechs, by contrast, often advance differentiated mechanisms or targeted combinations that may address unmet biological pathways and create opportunities for strategic partnerships or licensing transactions.

Channel and service providers such as specialty pharmacies and patient support vendors are increasingly strategic partners, delivering adherence programs, infusion coordination, and outcomes tracking that influence long-term treatment success. Contract research organizations and real-world evidence partners also play critical roles by enabling pragmatic studies and post-approval data collection. As competitive dynamics evolve, successful companies will integrate clinical evidence generation with commercial planning, leverage partnerships to bridge capability gaps, and maintain flexibility to respond to payer feedback and new clinical insights.

Actionable strategic imperatives for industry leaders to synchronize evidence generation, supply resilience, digital care integration, and localized market access planning

Industry leaders must act decisively to align clinical innovation with sustainable access and delivery models if they are to meaningfully improve outcomes for people living with IPF. First, invest in robust evidence generation that pairs randomized controlled data with real-world effectiveness and safety endpoints to support payer dialogues and clinical guideline updates. Complementary to evidence strategy, build flexible supply chains with near-term contingency plans and strategic supplier diversification to mitigate tariff and geopolitical risk while preserving consistent patient access.

Operationally, integrate digital monitoring and remote care capabilities into commercial offerings to support adherence, early adverse event detection, and longitudinal outcomes measurement. Collaborate with specialty pharmacies and home healthcare providers to streamline initiation processes and reduce administrative burden on clinicians. Finally, develop localized market access plans that align value communication with country-specific health technology assessment requirements and engage early with clinical opinion leaders to accelerate guideline adoption. By executing these priorities, leaders can translate scientific progress into tangible improvements in care delivery and patient experience.

Transparent, multi-source research methodology combining expert primary interviews, clinical literature synthesis, and scenario-driven supply chain risk analysis

The research methodology underpinning this report integrates multi-source evidence synthesis, expert clinician interviews, and rigorous qualitative analysis to ensure robust and actionable findings. Primary research included structured interviews with pulmonologists, clinical trial specialists, supply chain managers, and reimbursement experts to capture frontline perspectives on diagnostic pathways, therapeutic decision drivers, and operational bottlenecks. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical guidelines, and product monographs to validate clinical assertions and therapeutic context.

Analytic methods combined thematic coding of qualitative inputs with comparative assessments of treatment paradigms and distribution channel practices. Scenario analysis was employed to evaluate supply chain exposures and tariff-related risks, while stakeholder mapping informed recommendations on payer engagement and partnership prioritization. Throughout, the approach emphasized triangulation of evidence and transparent documentation of assumptions to support confident decision-making by clinical, commercial, and policy audiences.

Concise conclusion emphasizing the necessity of integrated evidence, operational resilience, and stakeholder collaboration to translate IPF innovations into improved patient outcomes

In conclusion, the idiopathic pulmonary fibrosis landscape is entering a period of pragmatic innovation where therapeutic advances, evolving care delivery models, and shifting trade dynamics converge to redefine access and outcomes. Improved mechanistic understanding and novel therapeutic strategies present genuine opportunities to alter disease trajectories, but realizing that potential demands coordinated investments in evidence, supply resilience, and patient-centric care models. Stakeholders who proactively align clinical development with payer needs and operational realities will be best positioned to translate scientific progress into durable value for patients.

As the ecosystem continues to evolve, continual engagement with clinicians, payers, and service providers will be essential to refine treatment algorithms, optimize adherence support, and ensure equitable access. The pathway forward requires both scientific rigor and pragmatic commercial execution, with a relentless focus on measurable improvements in lung function, quality of life, and system-level efficiencies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Idiopathic Pulmonary Fibrosis Market, by Therapeutic Class

  • 8.1. Antifibrotics
    • 8.1.1. Nintedanib
    • 8.1.2. Pirfenidone
  • 8.2. Immunosuppressants
    • 8.2.1. Corticosteroids
      • 8.2.1.1. Methylprednisolone
      • 8.2.1.2. Prednisone
    • 8.2.2. Immunomodulators
      • 8.2.2.1. Azathioprine
      • 8.2.2.2. Mycophenolate Mofetil

9. Idiopathic Pulmonary Fibrosis Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Idiopathic Pulmonary Fibrosis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Pharmacies

11. Idiopathic Pulmonary Fibrosis Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Home Healthcare Facilities
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Idiopathic Pulmonary Fibrosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Idiopathic Pulmonary Fibrosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Idiopathic Pulmonary Fibrosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Idiopathic Pulmonary Fibrosis Market

16. China Idiopathic Pulmonary Fibrosis Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AstraZeneca PLC
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. F. Hoffmann-La Roche Ltd.
  • 17.9. Galapagos NV
  • 17.10. Gilead Sciences, Inc.
  • 17.11. Glenmark Pharmaceuticals Ltd.
  • 17.12. GNI Group Ltd.
  • 17.13. Horizon Therapeutics PLC by Amgen Inc.
  • 17.14. Johnson & Johnson
  • 17.15. Lupin Ltd.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY NINTEDANIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PIRFENIDONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY METHYLPREDNISOLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOME HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ANTIFIBROTICS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)